Occupy Innovation: Neither the Military Nor the Market Does
by: Gregg Levine Saturday 21 January 2012 Truthout | News Analysis
Actress Anne Hathaway marches with demonstrators on the two-month anniversary of Occupy Wall Street. (Photo: Elana Levin)
Two days after thousands of police broke up the around-the-clock occupation of New York’s Zuccotti Park, tens of thousands of demonstrators converged downtown to celebrate the two-month anniversary of Occupy Wall Street and stress that with or without Zuccotti, the protest and its message remained strong and relevant.
One of those in the march, the actress Anne Hathaway, carried a sign that read “Blackboards not Bullets,” and though much attention was predictably paid to the 29-year-old star’s presence, the message she carried that day shouldn’t be ignored.
A month earlier, shortly after a company called Boston Dynamics unveiled a prototype of its “Legged Squad Support System” AlphaDog, a walking robot financed by DARPA, the Defense Advanced Research Projects Agency, Rachel Maddow featured the technological marvel in a segment contrasting current advances in military hardware with what is currently on offer for consumers.
Her featured guest in that segment was US Rep. Rush Holt (D-New Jersey). Holt had, a month earlier still, gone on record in the midst of Washington’s deficit hysteria arguing that the government should actually spend more on scientific research, writing that the framing of the budget debate set up a false choice between basic science and elementary education.
Nothing demonstrates the effectiveness of the young Occupy movement more than the rapid shift in frames. The “cut, cut, cut” of the manufactured deficit crisis that Holt had to fight against has been largely drowned out by the chant of “banks got bailed out; we got sold out” and the re-evaluation of spending priorities that came with nationwide demands for an accountable government acting in the service of the 99 percent.
But, to state the obvious, four months of Occupy has not been enough to really transform the way the federal government prioritizes spending, nor has the movement yet transformed the way the country evaluates real progress.
Join Us! Subscribe to WAMMToday from our blog website and “Follow” us. riseuptimes.wordpress.com.
WAMMToday is now on Facebook! Check the WAMMToday page for posts from this blog and more! “Like” our page today.
For instance, with December’s official end of US military operations in Iraq, and a promised drawdown coming in Afghanistan, as well, has anyone in official Washington (or in the commentariat, for that matter) started talking about what America will do with its “peace dividend?”
In fact, the beneficiaries of profligate wartime spending are marshaling their surrogates to warn that cuts in Pentagon spending will actually subtract valuable research dollars from the economy. Citing large contractors like SAIC, Computer Sciences Corporation and CACI International, a recent New York Times story tried to make the case that massive military spending in the last decade has been an important catalyst for the economy and for innovation in the broader marketplace.
If these companies – all three of which have been involved in major scandals over the last several years – stand for anything, however, it is that the unchecked expansion of the defense budget is a catalyst for shameless corruption. (An observation glaringly absent from the Times piece.)
Indeed, for all the sincere excitement that might spring up around robot dogs, or a stream of other “war dividends” that might find some purpose in the consumer marketplace – from high-resolution cameras to improved prosthetic limbs – the wow factor not only obscures the full cost of the innovation, but distorts the measure of innovation itself.
A Marketplace of Ideas?
Many conservatives (and neoliberals) love to argue that the marketplace is the best judge of winners and losers. Competition is the key to innovation, they argue. But in the consumer market, innovation isn’t always about providing a better product. Just as often, “innovation” means exploiting a leverageable point of difference or streamlining the manufacturing process in pursuit of better profit margins.
Was Coke Zero an innovation over Diet Coke? Was Nexium an innovation over Prilosec? Certainly, marketing said “yes,” but the research, at least in the case of the pharmaceuticals, stated otherwise:
It’s expensive to produce an innovative drug. On average, the bill runs to more than $400 million. So drug companies often take a less costly route to create a new product. They chemically rejigger an oldie but goodie, craft a new name, mount a massive advertising campaign and sell the retread as the latest innovative breakthrough.This strategy has shown great success for turning profits. Nexium, a “me-too” drug for stomach acid, has earned $3.9 billion for its maker, AstraZeneca, since it went on the market in 2001. The U.S. Food and Drug Administration classified three-fourths of the 119 drugs it approved last year as similar to existing ones in chemical makeup or therapeutic value….
Nexium illustrates the drug makers’ strategy. Many chemicals come in two versions, each a mirror image of the other: an L-isomer and an R-isomer. (The “L” is for left, the “R” is for right.) Nexium’s predecessor Prilosec is a mixture of both isomers. When Prilosec’s patent expired in 2001, the drug maker was ready with Nexium, which contains only the L-isomer.
Is Nexium better? So far, there’s no convincing evidence that it is….